Opioid Antagonist Market Players:
- Indivior PLC
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- •Regional Presence
- SWOT Analysis
- Alkermes.
- Titan Pharmaceuticals, Inc.
- Hikma Pharmaceuticals PLC
- Orexo AB
- Camurus AB
- Acura Pharmaceuticals.
- Collegium Pharmaceutical
- AstraZeneca
- Viatris Inc.
- Catalent, Inc
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of opioid antagonist is evaluated at USD 4.11 billion.
The global opioid antagonist market size was worth over USD 3.69 billion in 2025 and is poised to grow at a CAGR of around 12.5%, reaching USD 11.98 billion revenue by 2035.
North America is expected to dominate with a 38% revenue share in the opioid antagonist market, attributed to streamlined regulatory approvals and expanded access to naloxone through government-led distribution initiatives.
Key players in the market include Merck & Co., Inc., Siemens Healthcare GmbH, Boston Scientific Corporation, Johnson & Johnson Services, Inc., Valenta Pharmaceuticals Company, Novartis AG, Sanofi-Aventis Groupe, AbbVie Inc., Elli Lilly and Company.
